Intra-Medical Imaging LLC (“IMI”) develops and markets molecular imaging instruments to- detect cancer during surgery, identify vulnerable plaques in arteries and to deliver cell and gene therapies.
Molecular imaging is the most sensitive method of identifying abnormal tissues. The widespread application of molecular imaging in the operating room started with the advent of the sentinel node mapping for staging of melanoma and breast cancer. This technique is based on the injection of a radioactive tracer near the tumor site, and identifying the sentinel lymph nodes using a gamma detection probe.
IMI was founded in 1998, and launched its first product, the Node Seeker® gamma probe for sentinel node mapping. Next, IMI introduced the PET-Probes®, a novel intra-operative probe system for the detection of cancerous tissue based on PET radio-tracers such as FDG. These two product lines have been sold to hundreds of hospitals and surgery centers worldwide.
IMI builds its products in California, and sells directly to customers in the United States through independent sales representatives.
Recognizing the important role that molecular imaging will play in future healthcare, IMI has several novel products in various stages of development. These research and development efforts are being supported by Government grants, and are protected by four issued and three pending patents.